- Home
- EPOW vs ALXO Comparison
EPOW vs ALXO Comparison
Compare EPOW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPOW
- ALXO
- Stock Information
- Founded
- EPOW 2014
- ALXO 2015
- Country
- EPOW China
- ALXO United States
- Employees
- EPOW N/A
- ALXO N/A
- Industry
- EPOW Business Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- EPOW Consumer Discretionary
- ALXO Health Care
- Exchange
- EPOW Nasdaq
- ALXO Nasdaq
- Market Cap
- EPOW 24.1M
- ALXO 24.0M
- IPO Year
- EPOW 2021
- ALXO 2020
- Fundamental
- Price
- EPOW $0.92
- ALXO $0.64
- Analyst Decision
- EPOW
- ALXO Strong Buy
- Analyst Count
- EPOW 0
- ALXO 6
- Target Price
- EPOW N/A
- ALXO $3.30
- AVG Volume (30 Days)
- EPOW 4.6K
- ALXO 561.7K
- Earning Date
- EPOW 08-26-2025
- ALXO 08-12-2025
- Dividend Yield
- EPOW N/A
- ALXO N/A
- EPS Growth
- EPOW N/A
- ALXO N/A
- EPS
- EPOW N/A
- ALXO N/A
- Revenue
- EPOW $64,997,741.00
- ALXO N/A
- Revenue This Year
- EPOW N/A
- ALXO N/A
- Revenue Next Year
- EPOW N/A
- ALXO N/A
- P/E Ratio
- EPOW N/A
- ALXO N/A
- Revenue Growth
- EPOW 44.28
- ALXO N/A
- 52 Week Low
- EPOW $0.70
- ALXO $0.40
- 52 Week High
- EPOW $1.36
- ALXO $2.79
- Technical
- Relative Strength Index (RSI)
- EPOW 51.55
- ALXO 57.73
- Support Level
- EPOW $0.89
- ALXO $0.60
- Resistance Level
- EPOW $0.92
- ALXO $0.69
- Average True Range (ATR)
- EPOW 0.02
- ALXO 0.06
- MACD
- EPOW 0.00
- ALXO 0.00
- Stochastic Oscillator
- EPOW 90.74
- ALXO 63.95
About EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.